We compared the relative effects of dobutamine (5 µg/kg/min) and amrinone (1.0 mg/kg bolus followed by 10 µg/kg/min) on right and left ventricular function and pulmonary arterial pressures during weaning from cardiopulmonary bypass in patients with a mean preoperative pulmonary pressure >30 mmHg. Twenty patients scheduled for mitral valve replacement were studied in a prospective, randomized, double-blind trial.
Separating patients from cardiopulmonary bypass after cardiac surgery may be difficult because of myocardial depression and increased pulmonary vascular resistance. The process can be aggravated following mitral valve replacement because of pre-existing pulmonary hypertension, underlying rheumatic heart disease and right ventricular hypertrophy 1 . Also, adrenaline, noradrenaline and exogenous calcium may induce pulmonary vasocon-striction and increase pulmonary vascular resistance.
Selective FIII phosphodiesterase inhibitors such as amrinone and inotropes such as dobutamine have been used extensively to manage patients during separation from bypass. To assess their relative efficacy we undertook a prospective randomized double-blinded study of the acute postoperative haemodynamic effects of these two agents in patients with severe pulmonary hypertension.
METHODS
Twenty patients (five women and fifteen men) scheduled for elective mitral valve replacement with documented severe pulmonary hypertension on cardiac catheterization (mean pulmonary artery pressure >30 mmHg) were enrolled. We obtained institutional ethics committee approval (University of British Columbia) and written informed patient consent. Patients were randomized by use of a block randomization table. Patients were premedicated with oral lorazepam 0.05 mg/kg (maximum 4 mg). Anaesthesia was induced with diazepam 0.05 to 0.10 mg/kg and sufentanil 1 to 5 µg/kg, and neuromuscular blockade was achieved with pancuronium 0.15 mg/kg. Anaesthesia was maintained with an end-tidal concentration of isoflurane of 0-1.0% in air/oxygen (inspired oxygen concentration 0.50). Patients were ventilated to maintain normocapnia. Cardiovascular monitoring included ECG, pulse oximetry, a radial artery catheter, and, via the right internal jugular vein, a Right Ventricular Ejection Fraction/ Volumetric TD Catheter connected to an REF-1 Ejection Fraction/Cardiac Output Computer (Baxter Healthcare Corp., Edwards Critical Care Division, Irvine, CA, U.S.A.). A full haemodynamic profile including right ventricular ejection fraction (RVEF) was determined after induction of anaesthesia, at separation from bypass, and at 30 minutes and 180 minutes after separation from bypass.
Cardiopulmonary bypass was conducted with nonpulsatile flow and a membrane oxygenator. Patients were cooled to 28°C-33°C at the discretion of the surgeon. Myocardial protection was achieved with intermittent antegrade blood cardioplegia cooled to 6°C.
Following rewarming, prior to aortic cross-clamp removal, magnesium sulphate 2 g and methylprednisolone 15 mg/kg were administered by slow bolus into the bypass reservoir. An infusion of glyceryl trinitrate 0.5 µg/kg/min was commenced after cross-clamp removal according to our usual institutional practice. Adequate cardiac rhythm was established (sinus rhythm, or atrial fibrillation if this was present preoperatively) or single-or dual-chamber pacing was instituted. A pulmonary artery enddiastolic pressure of 15 mmHg or greater was achieved by volume loading. If the systemic systolic pressure was >100 mmHg at this point, the patient was excluded from the study because the use of an inotrope was deemed to be unnecessary. (No patient was excluded by this criterion.)
Patients then received either a placebo bolus coloured with a multivitamin injection (MV-1000, Sabex, Boucherville, Quebec, Canada) followed by an infusion of dobutamine 5 µg/kg/min prepared with MV-1000, or amrinone 1.0 mg/kg followed by an infusion at 10 µg/kg/min, each coloured with the same amount of MV-1000 as the dobutamine solutions. The MV-1000 concentration was chosen to produce very similar hues in both the amrinone and dobutamine preparations. Medications were prepared by a clinician not otherwise involved in the study.
If cardiac index remained less than 2.2 l/min/m 2 or systemic systolic pressure was below 90 mmHg, adrenaline was commenced and titrated to achieve adequate haemodynamic variables. Patients were transfused with remaining bypass reservoir blood to maintain pulmonary artery end-diastolic pressure above 15 mmHg.
This protocol was continued for three hours after weaning from CPB. After that time the doctor caring for the patient (who was not associated with the study) was informed of the contents of the treatment infusion by the clinician who had prepared the solutions and decided upon further therapy as appropriate.
Patient results were expressed as the difference between the value at a given time point and the value post-induction. The data depicted below, and in Figure 1 (a) to (f) are the mean absolute differences between a given time and the patients' post induction values. Standard deviation is shown in parentheses. Differences between groups at baseline were analysed by unpaired t-test where data were normally distributed and by Wilcoxon rank sum test when data were not normally distributed. Normality was assessed by visual inspection of histograms. Differences between groups and within groups over time were analysed by repeated measures ANOVA. Differences in the frequency of use of adrenaline was tested by Chi squared test. The doses of adrenaline used in each group were compared with Wilcoxon rank-sum test. Newman-Keul's post-hoc test was applied to each time point for variables for which ANOVA testing had demonstrated a significant (P<0.05) inter-group difference. A P value <0.05 was considered significant at post-hoc testing.
RESULTS
Ten patients in each group received each drug and there was no difference between the groups with regard to age, sex and weight. Patient characteristics are summarized in Table 1 . All patients were successfully weaned from cardiopulmonary bypass; no patients required intra-aortic balloon counterpulsation. No myocardial infarctions were observed in either group. All patients were discharged alive from hospital. There were no documented postoperative neurological deficits.
Values of baseline haemodynamic variables measured after induction of anaesthesia are shown in Table 2 . There were differences between the groups with respect to baseline mean arterial pressure (MAP), stroke volume index (SVI) and left ventricular stroke work index (LVSWI); the mean value for each was lower in the group that was to receive amrinone.
There were no differences in CPB time (165±50 min vs 142±50 min) or aortic cross-clamp time (125±38 min vs 114±59 min) between the amrinone group and the dobutamine group.
Results are shown in Table 3 . The patients receiving amrinone had an absolute increase in RVEF of 0.15 (±0.08) at separation from CPB compared to an increase of 0.04 (±0.11) in the dobutamine group. This difference persisted throughout the study period. (ANOVA; P<0.001) Similarly, those administered amrinone had a rise in CI of 1.38 litres/min/m 2 at separation versus a rise of 0.69 litres/min/m 2 in the dobutamine group. The difference between the groups throughout the study period was significant (ANOVA; P<0.05). As shown in Table 3 and Figure  1 (c) and (b) there was a more pronounced difference in SVI than cardiac index (CI) between the groups. There was also a fall in both pulmonary artery systolic pressure (PASP) and pulmonary artery diastolic pressure (PDSP) after bypass of 14.6 (±12.8) mmHg and 7.1 (±4.9) mmHg respectively in the amrinone group, compared to a small increase in PASP of 0.30 (±13.8) mmHg and a decrease in PADP of only 1.1 (±6.47) mmHg in the dobutamine group. These differences continued through the study (ANOVA; P<0.05). Those receiving amrinone had an increase in LVSWI of between 11.9 (±9.4) (at separation) and 14.4 (±11.5) (at 180 min post separation) g.m/m 2 compared with a decrease in LVSWI of between 5.4 (±8.2) (at separation) and 1.3 (±9.6) (at 30 min post separation) in the dobutamine group. This was in the presence of a greater decrease in PAOP in the amrinone group (P=0.0073).
There were no differences between the groups with respect to perioperative change in MAP (P=0.40), CVP (P=0.41), and RVSWI (P=0.88). An increase in HR in the dobutamine group compared to the amrinone group did not reach statistical significance (P=0.13)
The incidence of use of adrenaline was similar in the two groups (5/10, 5/10 and 7/10 in the amrinone group at separation, 30 min post separation and 180 min post separation respectively versus 4/10, 5/10 and 3/10 in the dobutamine group; P=0.425 no difference between groups with respect to dose of adrenaline used.
TABLE 3 Mean values (standard deviation in parentheses) for change over post induction baseline for haemodynamic variables recorded. A=amrinone group; D=dobutamine group. P value is derived by repeated measures analysis of variance of amrinone group vs. dobutamine group.(ANOVA) RVEF = right ventricular ejection fraction; CI = cardiac index; SVI = stroke volume index; LVSWI = left ventricular stroke work index; PASP = pulmonary artery systolic pressure; PADP = pulmonary artery diastolic pressure; PAWP = pulmonary artery wedge pressure; HR = heart rate; CVP = central venous pressure; MAP = mean arterial pressure and RVSWI = right ventricular stroke work index

DISCUSSION
The use of amrinone was associated with a decrease in right ventricular afterload by decreasing pulmonary arterial pressure, which resulted in an increased SVI and RVEF without a change in RVSWI. In contrast, an increase in LVSWI was seen, secondary to an increased SVI without a change in MAP, accompanied by a decrease in PAOP. Thus the effect on the right and left ventricles was quite different and these effects were of a greater degree than that seen with dobutamine. A greater effect on SVI and LVSWI than on CI was seen because of the slightly higher heart rates in the dobutamine group.
A RVEF pulmonary artery catheter was used to gain as much information about right heart mechanics during weaning from bypass in a group of patients in whom right ventricular dysfunction is thought to be a serious problem. Whilst some of the statistically significant results are the derived indices which are prone to larger errors than measured values, important differences between the groups also occurred in measured pulmonary pressures and the cardiac index. The amrinone group had a lower MAP, LVSWI and SVI at baseline, prior to therapy. Thus the difference in proportional changes in LVSWI and SVI would have been greater than the absolute differences depicted. Although the patients receiving amrinone had a worse baseline haemodynamic status as a group as indicated by the above variables, nonetheless this group had the larger absolute improvement in haemodynamic function.
Our study design was unique in that it was a randomized blinded trial of amrinone versus a catecholamine inotrope in patients with severe preoperative pulmonary hypertension.
Amrinone and dobutamine have been compared in an open labelled, prospective, randomized trial by Dupuis et al 2 in patients with preoperative left ventricular dysfunction undergoing myocardial revascularization who had a low cardiac index on separation from bypass. They found no haemodynamic differences between the groups, and a similar incidence of myocardial ischaemia in both groups. However there were six postoperative myocardial infarctions amongst the fifteen patients treated with dobutamine, as opposed to none among those treated with amrinone (Chi squared test; P=0.017).
The combination of amrinone and adrenaline has been found to result in a greater increase in SV, cardiac output (CO) and LVSWI than either agent alone after bypass in patients with adequate preoperative LV function (EF>0.45) 3 . In the doses used amrinone alone caused a similar increase to adrenaline alone in LVSWI, CO and SV. Amrinone appeared to cause a fall in pulmonary vascular resistance (PVR). However there were large differences between the four groups in baseline PVR. They also found that amrinone increased RVEF whilst adrenaline alone did not.
Amrinone has been studied in pulmonary hypertensive patients awaiting heart transplantation 4 . Compared to conventional therapy it resulted in a greater survival in patients awaiting transplantation as well as a greater reduction in pulmonary vascular resistance.
Our findings of an improvement in left ventricular performance support previous studies; however the * improvement in RVEF was greater than that found in another study 5 in which CI increased 14 to 23% and RVEF increased 16 to 28% over baseline. This was an uncontrolled study using a lower loading dose of 0.5 mg/kg but a higher infusion rate of 17 µg/kg/min. The improvement seen in CI and RVEF over the 30 minute study period probably was due to increasing serum and tissues levels with this regimen. Improvement in CI and a decrease in pulmonary arterial pressures has been reported in two uncontrolled cases using amrinone in combination with isoprenaline or dopamine 6 . A recent report 7 comparing amrinone with placebo in patients with poor left ventricular (LV) function, documented the need for adrenaline as "rescue" therapy in 14/19 patients in the "placebo" group compared to 1/20 in the amrinone group (P<0.00001). In their study the use of amrinone was shown to be associated with the same increase in HR and CI as the "placebo" group after CPB.
Keogh et al 8 compared the effects of another phosphodiesterase inhibitor, enoximone, and dobutamine in twenty patients with impaired LV function (LVEF<0.50) on haemodynamics before and after weaning from CPB. This was a prospective, randomized but unblinded study. There was no difference between the groups with respect to changes in CVP, PAOP, mean PAP, CI and HR. The latter two variables increased in both groups. In contrast to our study they found no differences between dobutamine (at 10 µg/kg/min) and enoximone on LVSWI and RVSWI. Although their patients had poor LV function preoperatively, it appeared that pulmonary pressures were not elevated perioperatively.
The amrinone and dobutamine drug regimens were chosen as usual starting dosages in our institution. It is not known whether a higher rate of infusion of dobutamine would have had a greater effect on measured haemodynamics. A non-significant rise in heart rate was seen in the dobutamine group; a higher dose may have resulted in a higher heart rate in this group. Some authors recommend a higher loading dose of amrinone 9 which in our study may have resulted in a greater difference between the groups. The requirement for adjuvant adrenaline was similar in the two groups suggesting that the doses of amrinone and dobutamine chosen were similarly potent.
Amrinone is unavailable in Australia; milrinone is the only FIII selective phosphodiesterase inhibitor available. It is fifteen to twenty times more potent, lacks the longterm deleterious effects on platelet number and function but otherwise is a very similar agent. In uncontrolled studies milrinone has been shown to be useful in weaning patients with low cardiac output off bypass 10, 11 .The pharmacology and clinical uses of milrinone has recently been reviewed 12 .
CONCLUSIONS
The use of amrinone resulted in an improved haemodynamic state after cardiopulmonary bypass when compared with dobutamine in this group of patients. In particular, pulmonary pressures were lower, while RVEF was increased. Greater increases in LVSWI and SVI were seen in the amrinone group. Amrinone is a useful agent during and after weaning patients with pre-existing pulmonary hypertension from bypass.
